1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Tibet Rhodiola Pharmaceutical Holding Co. Class A

Tibet Rhodiola Pharmaceutical Holding Co. Class A

600211.SS
Tibet Rhodiola Pharmaceutical Holding Co. Class ACN flagShanghai Stock Exchange
37.57
CNY
-1.46
- -
12.11BMarket Cap

Total Valuation

Tibet Rhodiola Pharmaceutical Holding Co. Class A carries a market capitalization of 12.11B, placing it among publicly traded companies globally. Its enterprise value stands at 9.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.11B
Enterprise Value9.51B

Share Statistics

Tibet Rhodiola Pharmaceutical Holding Co. Class A currently has 322.32M shares outstanding.

Shares Outstanding322.32M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Tibet Rhodiola Pharmaceutical Holding Co. Class A trades at a trailing price-to-earnings ratio of 11.86. The price-to-sales ratio is 4.15, and the price-to-book ratio stands at 4.31.

PE Ratio11.86
PS Ratio4.15
PB Ratio4.31
P/TBV Ratio2.94
P/FCF Ratio322.56
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Tibet Rhodiola Pharmaceutical Holding Co. Class A trades at an EV/EBITDA multiple of 9.12 and an EV/FCF ratio of 235.22. The EV/Sales ratio of 3.34 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.12 provides insight into valuation relative to core operating earnings.

EV / Sales3.34
EV / EBITDA9.12
EV / EBIT9.12
EV / FCF235.22

Financial Position

Tibet Rhodiola Pharmaceutical Holding Co. Class A maintains a current ratio of 2.94, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.52, indicating elevated leverage, while an interest coverage ratio of 250.00 demonstrates strong ability to service its debt obligations.

Current Ratio2.94
Quick Ratio2.11
Debt / Equity16.52
Debt / EBITDA0.66
Interest Coverage250.00

Financial Efficiency

Tibet Rhodiola Pharmaceutical Holding Co. Class A posts a return on equity of 38.68 and a return on invested capital of 19.71.

Return on Equity (ROE)38.68
Return on Assets (ROA)18.10
Return on Invested Capital (ROIC)19.71
Return on Capital Employed (ROCE)29.83
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.31

Taxes

Over the trailing twelve months, Tibet Rhodiola Pharmaceutical Holding Co. Class A has paid 91.75M in income taxes, reflecting an effective tax rate of 8.39.

Income Tax91.75M
Effective Tax Rate8.39

Stock Price Statistics

Tibet Rhodiola Pharmaceutical Holding Co. Class A's stock has gained approximately 2.42639% over the past 52 weeks. The 50-day moving average sits at 39.06, while the 200-day moving average is 42.35.

Beta (5Y)N/A
52-Week Price Change2.42639%
50-Day Moving Average39.06
200-Day Moving Average42.35
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Tibet Rhodiola Pharmaceutical Holding Co. Class A generated 2.84B in revenue and converted that into 995.47M in net income, yielding earnings per share of 3.12. EBITDA reached 1.04B, while operating income came in at 1.04B.

Revenue2.84B
Gross Profit2.66B
Operating Income1.04B
Pretax Income1.09B
Net Income995.47M
EBITDA1.04B
EBIT1.04B
Earnings Per Share (EPS)3.12

Balance Sheet

Tibet Rhodiola Pharmaceutical Holding Co. Class A holds 3.03B in cash and equivalents against 693.24M in total debt, resulting in a net debt position of -1.45B. Total book value stands at 2.74B, with working capital of 2.78B providing operational flexibility.

Cash & Cash Equivalents3.03B
Total Debt693.24M
Net Debt-1.45B
Equity (Book Value)2.74B
Book Value Per Share8.54
Working Capital2.78B

Cash Flow

After subtracting -36.59M in capital expenditures, free cash flow totaled -36.59M - equivalent to -0.11 per share.

Operating Cash FlowN/A
Capital Expenditures-36.59M
Free Cash Flow-36.59M
FCF Per Share-0.11

Margins

Tibet Rhodiola Pharmaceutical Holding Co. Class A operates with a gross margin of 93.60, reflecting its pricing power and cost economics. The operating margin of 36.68 and net profit margin of 35.02 provide insight into operational efficiency.

Gross Margin93.60
Operating Margin36.68
Pretax Margin38.47
Profit Margin35.02
EBITDA Margin36.68

Dividends & Yields

The company's payout ratio of 63.45 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share2.00
Dividend YieldN/A
Payout Ratio63.45
Shareholder Yield5.86
FCF Yield0.31

Stock Splits

Tibet Rhodiola Pharmaceutical Holding Co. Class A's most recent stock split took place on April 30, 2024 with a 10:13 split ratio.

Last Split Date4/30/2024
Split Ratio10:13

Scores

Tibet Rhodiola Pharmaceutical Holding Co. Class A posts an Altman Z-Score of 7.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.20